Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT3212 Monotherapy or in Combination With BNT327 in Advanced Solid Tumors
NCT07147348Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of BNT3212 in solid tumor (advanced stage), sponsored by BioNTech SE. Started Aug 2025; status: recruiting.
02
Drugs
BNT3212
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07147348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07147348.